Prime Medicine stock soars amid gene editing sector momentum

Investing.com -- Prime Medicine (NASDAQ: PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE: LLY) acquisition deal for Verve Therapeutics (NASDAQ: VERV) last month.

The gene editing company has seen its shares surge approximately 160% since mid-June, building on momentum that began after a management change on May 19. The rally comes as investors reassess valuations in the gene editing sector following significant M&A activity.

Several factors appear to be driving Prime Medicine’s upward trajectory, including Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics, a significant price/valuation discrepancy compared to peers, substantial insider buying of 329,000 shares in the open market since mid-May, and high short interest exceeding 30% of float.

The gene editing sector has seen increased acquisition interest, as evidenced by AbbVie’s (NYSE: ABBV) recent $2.1 billion purchase of Capstan Therapeutics on June 30.

Jones Trading analyst Soumit Roy commented on the sector’s outlook: "VERV’s Phase 1b data was sufficient to trigger an M&A, and we believe PRME could get to the same place as they start announcing their clinical data in 2027."

While Prime Medicine has yet to produce clinical data, Lilly’s acquisition of Verve suggests pharmaceutical companies are increasingly interested in gene editing technologies for treating larger market diseases, not just rare conditions with acute unmet needs.

You May Also Be Interested In

• Thinking Machines Lab seeks $1b raise at $40b valuation - report
• Jefferies raises long-term uranium prices outlook
• Aerovironment secures landmark $465M U.S. Army contract for laser defense systems